A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0011359C (M7824) in Subjects With Metastatic or Locally Advanced Solid Tumors With Expansion to Selected Indications in Asia

Trial Profile

A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0011359C (M7824) in Subjects With Metastatic or Locally Advanced Solid Tumors With Expansion to Selected Indications in Asia

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Apr 2018

At a glance

  • Drugs MSB 0011359C (Primary)
  • Indications Gastric cancer; Oesophageal cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Merck KGaA
  • Most Recent Events

    • 11 Apr 2018 Planned End Date changed from 6 Feb 2019 to 31 Dec 2019.
    • 11 Apr 2018 Planned primary completion date changed from 30 Jul 2018 to 31 Dec 2019.
    • 30 Jan 2018 Planned End Date changed from 6 Mar 2019 to 6 Feb 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top